June 11, 2020
Via: MedPageTodayThe general treatment of advanced HER2-positive breast cancer has typically consisted of a combination of chemotherapy and the monoclonal antibodies trastuzumab and pertuzumab as a first-line treatment, and the antibody-drug conjugate T-DM1 in the second line. “Once these treatments were […]